Follow
Anna Tutusaus
Anna Tutusaus
IIBB-csic
Verified email at iibb.csic.es
Title
Cited by
Cited by
Year
Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation
C Bárcena, M Stefanovic, A Tutusaus, L Joannas, A Menéndez, ...
Journal of hepatology 63 (3), 670-678, 2015
1242015
Mitochondrial glutathione: recent insights and role in disease
M Marí, E de Gregorio, C de Dios, V Roca-Agujetas, B Cucarull, ...
Antioxidants 9 (10), 909, 2020
1192020
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
A Tutusaus, M Stefanovic, L Boix, B Cucarull, A Zamora, L Blasco, ...
Oncotarget 9 (24), 16701, 2018
622018
Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer
C Bárcena, M Stefanovic, A Tutusaus, GA Martinez-Nieto, L Martinez, ...
Scientific reports 5 (1), 7916, 2015
592015
Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation
Á De Mingo, E De Gregorio, A Moles, N Tarrats, A Tutusaus, A Colell, ...
Cell Death & Disease 7 (11), e2464-e2464, 2016
552016
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
M Stefanovic, A Tutusaus, GA Martinez-Nieto, C Bárcena, E de Gregorio, ...
Oncotarget 7 (7), 8253, 2016
512016
Neurogenin3 cooperates with Foxa2 to autoactivate its own expression
M Ejarque, S Cervantes, G Pujadas, A Tutusaus, L Sanchez, R Gasa
Journal of Biological Chemistry 288 (17), 11705-11717, 2013
502013
A functional role of GAS6/TAM in nonalcoholic steatohepatitis progression implicates AXL as therapeutic target
A Tutusaus, E de Gregorio, B Cucarull, H Cristóbal, C Aresté, I Graupera, ...
Cellular and molecular gastroenterology and hepatology 9 (3), 349-368, 2020
472020
Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances
B Cucarull, A Tutusaus, P Rider, T Hernáez-Alsina, C Cuño, ...
Cancers 14 (3), 621, 2022
462022
Role of vitamin K-dependent factors protein S and GAS6 and TAM receptors in SARS-CoV-2 infection and COVID-19-associated immunothrombosis
A Tutusaus, M Marí, JT Ortiz-Pérez, GAF Nicolaes, A Morales, ...
Cells 9 (10), 2186, 2020
442020
Growth arrest-specific factor 6 (GAS6) is increased in COVID-19 patients and predicts clinical outcome
A Morales, S Rojo Rello, H Cristóbal, A Fiz-López, E Arribas, M Marí, ...
Biomedicines 9 (4), 335, 2021
222021
Regorafenib alteration of the BCL-xL/MCL-1 ratio provides a therapeutic opportunity for BH3-mimetics in hepatocellular carcinoma models
B Cucarull, A Tutusaus, M Subías, M Stefanovic, T Hernáez-Alsina, L Boix, ...
Cancers 12 (2), 332, 2020
212020
Antioxidants threaten multikinase inhibitor efficacy against liver cancer by blocking mitochondrial reactive oxygen species
B Cucarull, A Tutusaus, T Hernáez-Alsina, P Garcia de Frutos, M Reig, ...
Antioxidants 10 (9), 1336, 2021
162021
Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis
M Marí, A Tutusaus, PG de Frutos, A Morales
Journal of Hepatology 64 (4), 983-984, 2016
102016
Wnt9a deficiency discloses a repressive role of Tcf7l2 on endocrine differentiation in the embryonic pancreas
G Pujadas, S Cervantes, A Tutusaus, M Ejarque, L Sanchez, A García, ...
Scientific Reports 6 (1), 1-15, 2016
92016
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. Oncotarget. 2016; 7: 8253–8267
M Stefanovic, A Tutusaus, GA Martinez-Nieto, C Bárcena, E de Gregorio, ...
5
Sorafenib/Regorafenib resistance and BH3-mimetics efficacy in hepatocellular carcinoma treatment is determined by mitochondrial changes in the BCL-2 profile
A Tutusaus, M Stefanovic, B Cucarull, M Mari, L Boix, M Reig, J Bruix, ...
Journal of hepatology 68, S686-S687, 2018
32018
Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome. Biomedicines 2021, 9, 335
A Morales, S Rojo Rello, H Cristóbal, A Fiz-López, E Arribas, M Marí, ...
s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021
22021
Targeting mitochondrial function with the BCL-2 inhibitor ABT-263 increases therapy efficacy and evades sorafenib resistance
A Morales, A Tutusaus, JC Fernández-Checa, M Marí, M Stefanovic
22016
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice
C Cuño-Gómiz, E de Gregorio, A Tutusaus, P Rider, N Andrés-Sánchez, ...
Biology of sex Differences 14 (1), 85, 2023
12023
The system can't perform the operation now. Try again later.
Articles 1–20